Pfizer stock slips as new products support higher 2026 outlook
Published on 11/09/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer raises guidance as new products grow
- Launched and acquired products generated 3.8 billion US dollars in third-quarter revenue and grew 32 percent operationally.
- Pfizer lifted its 2026 revenue outlook and raised its adjusted earnings-per-share range.
- Pipeline progress and execution remain central to the growth case beyond COVID products.
Pfizer raised its 2026 financial outlook after third-quarter performance showed stronger contributions from newer and acquired medicines. In its official third-quarter update, the drugmaker said these products grew 32 percent operationally and generated 3.8 billion US dollars of quarterly revenue.
New products offset COVID pressure
Pfizer reported third-quarter revenue of 16.6 billion US dollars, broadly flat operationally from a year earlier. Excluding Comirnaty and Paxlovid, revenue increased 7 percent operationally as Eliquis, Padcev, the Vyndaqel family, Nurtec and Lorbrena helped offset weaker COVID product sales.
Pfizer now expects 2026 revenue of 62.0 billion to 64.0 billion US dollars, compared with its previous range of 60.5 billion to 62.5 billion US dollars. The company also raised and narrowed its adjusted diluted earnings-per-share outlook to 2.95 to 3.05 US dollars from 2.80 to 3.00 US dollars.
Pipeline execution remains the test
The company said it had advanced eight pivotal study starts, one pivotal readout and two regulatory decisions since its previous quarterly earnings update. Pfizer invested 8.3 billion US dollars in research and development during the first nine months of 2026 across oncology, vaccines, inflammation and immunology, and internal medicine.
Pfizer stock traded at 26.12 euros on Lang & Schwarz at 17:09 CET on Monday, November 9, 2026, 0.76 percent below the Xetra close of Friday, November 6, at 26.32 euros. This daily comparison is separate from the 1.21 percent decline from the 26.44-euro Lang & Schwarz quote in the latest relevant report at 14:00 CET.
Pfizer Inc. Stock Facts
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Primary exchange: New York Stock Exchange
- Lang & Schwarz price: 26.12 euros at 17:09 CET on November 9, 2026
- Daily comparison: 0.76 percent below the Xetra close of November 6, 2026
- Xetra close: 26.32 euros on November 6, 2026
The broader U.S. equity market is tracked through the S&P 500, while Pfizer's next investment milestones are guidance delivery and further pipeline progress.
More news and analyses on Pfizer stock will focus on newer-product growth, COVID revenue trends and regulatory progress.
